Abstract
An intracellular hallmark of Alzheimer’s Disease (AD) is accumulation of hyperphosphorylated tau as paired helical filaments (PHF). A significant advance in understanding the behavior of tau occurred when it was reported that VQIVYK hexapeptide motif is responsible for initiating the process of aggregation. In the last years, a great number of Tau aggregation inhibitors have been developed, including flavonoids. However, the binding mode of these potential drugs is not well established. In this work, the behavior and conformational stability of the Tau hexapeptide306VQIVYK311 were investigated in the presence of two known flavonoid inhibitors using Molecular Interaction Fields (MIFs), pharmacophore perception and molecular dynamics (MD) simulations. We have also proposed a likely binding mode for such inhibitors with the hexapeptide, which agrees with experimental data and is able to explain structure-activity relationships between different flavonoids.
Keywords: Alzheimer’s disease, tau protein, flavonoids, molecular interaction fields, pharmacophore perception, molecular dynamics simulations
Current Bioactive Compounds
Title:In Silico Binding Mode Proposed for Flavonoid Ligands of Tau Protein with Interest in Alzheimer's Disease
Volume: 9 Issue: 1
Author(s): Susimaire Pedersoli-Mantoani, Carlos Henrique Tomich de Paula da Silva and Vinicius Barreto da Silva
Affiliation:
Keywords: Alzheimer’s disease, tau protein, flavonoids, molecular interaction fields, pharmacophore perception, molecular dynamics simulations
Abstract: An intracellular hallmark of Alzheimer’s Disease (AD) is accumulation of hyperphosphorylated tau as paired helical filaments (PHF). A significant advance in understanding the behavior of tau occurred when it was reported that VQIVYK hexapeptide motif is responsible for initiating the process of aggregation. In the last years, a great number of Tau aggregation inhibitors have been developed, including flavonoids. However, the binding mode of these potential drugs is not well established. In this work, the behavior and conformational stability of the Tau hexapeptide306VQIVYK311 were investigated in the presence of two known flavonoid inhibitors using Molecular Interaction Fields (MIFs), pharmacophore perception and molecular dynamics (MD) simulations. We have also proposed a likely binding mode for such inhibitors with the hexapeptide, which agrees with experimental data and is able to explain structure-activity relationships between different flavonoids.
Export Options
About this article
Cite this article as:
Pedersoli-Mantoani Susimaire, Henrique Tomich de Paula da Silva Carlos and Barreto da Silva Vinicius, In Silico Binding Mode Proposed for Flavonoid Ligands of Tau Protein with Interest in Alzheimer's Disease, Current Bioactive Compounds 2013; 9 (1) . https://dx.doi.org/10.2174/1573407211309010004
DOI https://dx.doi.org/10.2174/1573407211309010004 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Does an Interdisciplinary Network Improve Dementia Care? Results from the IDemUck-Study
Current Alzheimer Research Antagonism of Endothelin (ETA and ETB) Receptors During Renovascular Hypertension-Induced Vascular Dementia Improves Cognition
Current Neurovascular Research Imaging Neuroinflammation in Ischemic Stroke and in the Atherosclerotic Vascular Disease
Current Vascular Pharmacology RAS Inhibition Attenuates Cognitive Impairment by Reducing Blood- Brain Barrier Permeability in Hypertensive Subjects
Current Hypertension Reviews Closure of Patent Foramen Ovale: When and How?
Current Vascular Pharmacology Visual Spatial Attention Training Improve Spatial Attention and Motor Control for Unilateral Neglect Patients
CNS & Neurological Disorders - Drug Targets The Risk of Adverse Drug Reactions in Older Patients: Beyond Drug Metabolism
Current Drug Metabolism Differences in Relative Levels of 88 microRNAs in Various Regions of the Normal Adult Human Brain
MicroRNA The Renin-Angiotensin System in the Mammalian Central Nervous System
Current Protein & Peptide Science Antibodies As Promising Novel Neuroprotective Agents in the Central Nervous System Injuries
Central Nervous System Agents in Medicinal Chemistry Oral and Written Naming in Alzheimer’s Disease: A Longitudinal Study
Current Alzheimer Research Molecular Links Between Alzheimer's Disease and Gastrointestinal Microbiota: Emphasis on Helicobacter pylori Infection Involvement
Current Molecular Medicine Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications
Current Pharmaceutical Design Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design Reconstructing the Hsp90/Tau Machine
Current Enzyme Inhibition EEG Upper/Low Alpha Frequency Power Ratio and the Impulsive Disorders Network in Subjects with Mild Cognitive Impairment.
Current Alzheimer Research Importance of P-gp PET Imaging in Pharmacology
Current Pharmaceutical Design Neuroimaging Correlates of 22q11.2 Deletion Syndrome: Implications for Schizophrenia Research
Current Topics in Medicinal Chemistry Music Therapy in the Management of Dementia
Current Psychiatry Research and Reviews Oxidative Stress: Apoptosis in Neuronal Injury
Current Alzheimer Research